Interim report January - March 2007

Interim report January - March 2007

•	Net sales in the first quarter amounted to 118.9 (120.6) MSEK. At comparable
exchange rates sales increased by 5%.

•	The operating result for the first quarter amounted to 7.2 (-12.2) MSEK.

•	The net result for the first quarter amounted to 7.2 (-20.8) MSEK and the
result per share to 0.08 (-0.24) SEK.

•	The cash flow from operating activities amounted to 14.2 (-11.6) MSEK.

•	Net sales in the last 12 months amounted to 517.8 MSEK and the operating
result to 25.9 MSEK.

•	At the end of March the company introduced two new products at the congress of
the ACS, the American Chemical Society, in Chicago; a new, modified system for
evaporation, V10 and SNAP, a newly developed series of consumables for
purification, which were both received positively. 

•	McMaster University and Biotage have signed an agreement regarding the
development of a new chemistry platform which will enable a more efficient
production within the areas of molecular imaging and therapy agents. These areas
address new markets of interest to Biotage with the existing product portfolio.

•	In accordance with authorization from the Annual General Meeting on April 27,
2006 a global share option program for the Group's employees was approved.

For further information, please contact:
Torben Jörgensen, president and CEO, phone: +46 707 49 05 84
Mats-Olof Wallin, CFO, phone: +46 705 93 52 73

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 business and products from the company
Argonaut were acquired, further strengthening the product range in medicinal
chemistry. The customers include the world's top 30 pharma companies, the
world's top 20 biotech companies, and leading academic institutes. The company
is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany
and several other European countries. Biotage has 332 employees and had sales of
520 MSEK in 2006. Biotage is listed on the Stockholm stock exchange. Website:
www.biotage.com